P. N. Lara

发表

Acetaminophen and diphenhydramine as premedication for platelet transfusions: A prospective randomized double‐blind placebo‐controlled trial

L. Beckett, P. Lara, J. Tuscano, 2002, American journal of hematology.

A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109

S. Dakhil, P. Gumerlock, E. Crawford, 2005, Cancer Chemotherapy and Pharmacology.

Non-small-cell lung cancer progression after first-line chemotherapy

D. Gandara, D. Lau, David R. Gandara, 2002, Current treatment options in oncology.

Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines

D. Gandara, P. Mack, W. Holland, 2015, Journal of Cancer Research and Clinical Oncology.

XL647—A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatment with Either Gefitinib or Erlotinib

H. Wakelee, T. Lynch, V. Miller, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors

L. Beckett, D. Gandara, P. Lara, 2012, Investigational New Drugs.

A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma

D. Gandara, D. Quinn, P. Frankel, 2011, International Journal of Clinical Oncology.

Impact of an Interactive On-line Tool on Therapeutic Decision-Making for Patients with Advanced Non–Small-Cell Lung Cancer

L. Beckett, D. Gandara, M. Edelman, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Bortezomib for Patients with Advanced-Stage Bronchioloalveolar Carcinoma: A California Cancer Consortium Phase II Study (NCI 7003)

D. Gandara, R. Salgia, M. Edelman, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study

L. Beckett, D. Gandara, A. Davies, 2007, Investigational New Drugs.

Use of recombinant microRNAs as antimetabolites to inhibit human non-small cell lung cancer

Aiming Yu, Mei-Juan Tu, Hongwu Chen, 2023, Acta pharmaceutica Sinica. B.

Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications

P. Lara, C. Evans, C. Pan, 2007, World Journal of Urology.

The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis

J. Pignon, P. Laurent-Puig, C. Punt, 2014, The Pharmacogenomics Journal.

Clinical implications of neuroendocrine differentiation in prostate cancer

Joon-ha Ok, J. Yang, P. Lara, 2007, Prostate Cancer and Prostatic Diseases.

DNA methylation landscapes in advanced prostate cancer

Luke A. Gilbert, Kathleen E. Houlahan, S. Batzoglou, 2020, Nature Genetics.

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma

K. Do, E. Jonasch, K. Shaw, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment.

D. Gandara, P. Lara, F. Meyers, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model

H. Kung, R. deVere White, H. Nguyen, 2014, Oncogene.

Lung cancer vaccines

D. Gandara, A. Davies, Cheryl Ho, 2007 .

H. Wakelee, V. Miller, M. Pietanza, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Treatment options in androgen-independent prostate cancer.

P. Lara, F. Meyers, P. N. Lara, 1999, Cancer investigation.

Inhibition of Akt pathways in the treatment of prostate cancer

P. Mack, P. Lara, C. Evans, 2007, Prostate Cancer and Prostatic Diseases.

Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial.

S. Groshen, J. Pinski, D. Gandara, 2009, Clinical genitourinary cancer.